Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) shares saw an uptick in trading volume on Monday following insider buying activity. 4,418,919 shares traded hands during trading, an increase of 3,113% from the previous session’s volume of 137,544 shares.The stock last traded at $0.74 and had previously closed at $0.69.
Specifically, major shareholder John K. Jr. Scott bought 4,000,000 shares of the company’s stock in a transaction dated Tuesday, June 18th. The shares were bought at an average price of $0.75 per share, for a total transaction of $3,000,000.00. Following the completion of the acquisition, the insider now directly owns 5,113,078 shares of the company’s stock, valued at $3,834,808.50. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders bought 4,011,300 shares of company stock worth $3,018,490 in the last 90 days.
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.24) EPS for the quarter. The company had revenue of $0.14 million during the quarter.
An institutional investor recently raised its position in Navidea Biopharmaceuticals stock. Virtu Financial LLC boosted its position in Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) by 94.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 186,972 shares of the biopharmaceutical company’s stock after buying an additional 90,647 shares during the quarter. Virtu Financial LLC owned approximately 0.09% of Navidea Biopharmaceuticals worth $26,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Navidea Biopharmaceuticals Company Profile (NYSEAMERICAN:NAVB)
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.
Read More: CD Ladder
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.